AACR 2023 | The future of arginine deprivation therapy in lung cancer

Peter Szlosarek, MD, PhD, Barts Cancer Institute, London, UK, provides an overview of the emerging role of pegargiminase, a form of arginine deprivation therapy, in lung cancer. Despite the arrival of ipilimumab and nivolumab, pegargiminase will provide a novel chemotherapy-based treatment option for non-epithelioid mesothelioma, which currently has limited treatment options. Pegargiminase will additionally be assessed in small cell lung cancer with atezolizumab. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.